ROBO1 and pancreatic ductal adenocarcinoma: Notably, three phase I/II clinical trials (NCT03940820, NCT03941457, NCT03931720) conducted in Chinese cohorts evaluated allogeneic ROBO1-specific CAR-NK-92 cell immunotherapy for pancreatic ductal adenocarcinoma (PDAC) and ROBO1-expressing solid tumors (100–102).